Haemonetics Corporation (HAE) - 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2001
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of blood. The company operates as a single segment focused on blood processing systems, including surgical blood salvage, automated plasma collection, automated platelet collection, automated red cell collection, and cell processing. The company markets to hospitals, blood banks, and commercial plasma centers in over 50 countries.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2001 | Fiscal 2000 | Fiscal 1999 |
|---|---|---|---|
| Net Revenues | $293,860 | $280,612 | $284,513 |
| Gross Profit | $142,413 | $131,457 | $133,647 |
| Gross Margin | 48.5% | 46.8% | 47.0% |
| Operating Income | $13,420 | $20,443 | $31,615 |
| Net Income | $7,236 | $15,370 | $21,077 |
| Diluted EPS | $0.278 | $0.580 | $0.784 |
| Operating Cash Flow | $61,010 | $58,397 | $51,101 |
| Total Debt | $69,719 | $74,202 | $59,171 |
| Working Capital | $139,717 | $121,443 | $162,188 |
| Current Ratio | 2.8 | 2.4 | 3.3 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 4.7% to $293.9 million. On a constant currency basis, growth was 2.6%. Growth was driven by Red Cell disposables (up 34.3% constant currency), Surgical disposables (up 4.6%), and Plasma disposables (up 2.5%).
- Profitability Decline: Operating income decreased 34.4% to $13.4 million, and Net Income dropped 52.9% to $7.2 million. This decline was primarily due to significant non-recurring charges related to the acquisition of Transfusion Technologies Corporation.
- Acquisition Charges: The company recorded $18.6 million in In-Process Research and Development (IPR&D) charges and $4.6 million in other unusual charges (severance, bonuses, and investment write-downs) associated with the Transfusion Technologies acquisition.
- Expense Increases: R&D expenses rose 27.4% to $19.0 million to support new product development. SG&A expenses increased 4.6% to $86.7 million, partially offset by $1.0 million in savings from the "CORE" operational efficiency program.
- Equipment Sales: Equipment revenue decreased 10.6% as the company shifted strategy toward placing company-owned equipment on loan rather than selling it, aligning with customer preferences.
Guidance, Outlook, and Risks
- Strategic Acquisitions: The acquisition of Transfusion Technologies adds centrifuge-based technology (Dynamic Disk) for red cell and plasma collection. Key products include the Chairside Separator (98% complete, FDA submission expected FY2002) and Red Cell Collector (65% complete, sales expected FY2004).
- Regulatory Milestones: The company received FDA clearance for the ACP 215 automated cell processing system (extending frozen red cell shelf life to 14 days) and an automated red cell collection system with leukoreduction capabilities.
- Market Risks: Over two-thirds of revenues are generated outside the U.S., exposing the company to foreign exchange volatility. The company uses forward contracts to hedge these risks. Regulatory changes in blood collection (e.g., in China) and the enforcement of manual vs. automated collection standards remain a risk.
- Accounting Changes: The company adopted SFAS No. 133 regarding derivative instruments effective April 1, 2001, which will require recording fair values of forward contracts on the balance sheet.
- Outlook: Management expects the effective tax rate for the next fiscal year to be approximately 28%. The company continues to invest heavily in R&D to fuel future top-line growth.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and regulatory approval status for the Chairside Separator and Red Cell Collector technologies acquired from Transfusion Technologies.
- China Operations: Review the status of the $9.5 million write-down related to sales-type leases in China and the enforceability of the Chinese government's mandate for automated plasma collection.
- Customer Concentration: Note that one unaffiliated Japanese customer accounted for 22.7% of total accounts receivable and significant revenue; monitor payment history and credit risk.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically regarding the $40 million Senior Notes and the new $10 million real estate mortgage.
- Stock-Based Compensation: Review the pro-forma impact of SFAS No. 123, which would have reduced 2001 Net Income to $0.65 million and Diluted EPS to $0.025 if fair value accounting were applied.